[1] |
YOU Rongli, HUANG Yurong, MAORui, HAI Lina, WANG Yingli, WANG Yan.
Mechanism of compound kushen injection in the treatment of lung cancer based on serum metabolomics and network pharmacology
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 988-999.
|
[2] |
HOU Qiong, LIU Fei, CHEN Chuanrong.
Immunotherapy combined with anti-angiogenic drugs and chemotherapy in negative driver gene and advanced non-small cell lung cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 775-779.
|
[3] |
FU Ting, LI Fang, PAN Dayan, XIA Yuanyuan, ZHANG Qiuyuan.
miR-718 from exosomes of lung cancer cells induces angiogenesis by targeting PTEN
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 624-632.
|
[4] |
LI Fei, DING Huiqin, CHEN Mengjing.
Isonlosinine induces autophagy of PC9 cells by ERK signaling pathway in lung cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1235-1240.
|
[5] |
LIU Jiajun, QUE Zujun, TIAN Jianhui.
Comparative study on the ability of active ingredients in Jinfukang to decrease neutrophils recruiting by lung cancer circulating tumor cells
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 1-9.
|
[6] |
SU Yang, ZHOU Feng, DING Jinlei.
Effects of esketamine combined with sufentanil on postoperative analgesia and emotion after thoracoscopic radical resection of lung cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 59-65.
|
[7] |
HUANG Xiaoming, DU Ye, LIN Shaoming, SHEN Guanle.
Exploratory study of the influence of respiratory microbiology on the efficacy of PD-1 inhibitors monotherapy for patients with advanced non-small cell lung cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 66-74.
|
[8] |
ZHANG Kexin, JIA Wenjing, CUI Jiawen, AO Luyao, ZHOU Fang, WANG Guangji, LIU Jiali.
Advances in the research and clinical application of the third generation EGFR TKIs in the treatment of non-small cell lung cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1016-1030.
|
[9] |
ZHAO Ziwen, FAN Fangtian, JIANG Zhijun.
Induced bronchial associated lymphoid tissue (iBALT) formation and research of related lung diseases
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 353-360.
|
[10] |
CUI Hua, YAN Hongxia, YIN Mei.
Effects of down-regulating lncRNA LINC00176 on cisplatin resistance and autophagy in lung cancer A549/DDP cells
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(6): 616-623.
|
[11] |
HUANG Yiting, SHEN Aizong.
Clinical research progress of afatinib therapy for lung cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 474-480.
|
[12] |
PEI Qinghua, SUN Jianli.
Research progress of Osimertinib acquired resistance
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(1): 105-112.
|
[13] |
CAO Ying, TU Linglan, WANG Xiaoju, ZHENG Xiaoliang.
Progress on TMPRSS2-ERG fusion gene product transcription regulation mechanism in prostate cancer cells
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(7): 791-795.
|
[14] |
WEI Weitian, CHEN Sheng, WANG Liang, ZENG Jian.
Breviscapine induced the apoptosis of non-small cell lung cancer A549 cells
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(6): 618-624.
|
[15] |
YANG Guoliang, HU Dandan, XU Yikai, LOU Liming.
Yiqi Huoxue decoction inhibits malignant biological behavior of human lung cancer cells via the miR-21/PTEN signaling pathway
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(5): 512-518.
|